Arcutis Biotherapeutics Inc. (ARQT) PT Raised to 'Street High' $80 at Cowen

Go back to Arcutis Biotherapeutics Inc. (ARQT) PT Raised to 'Street High' $80 at Cowen

Arcutis Biotherapeutics Inc. (ARQT) Prices 5.5M Share Upsized Common Offering at $35/Sh

February 3, 2021 5:41 AM EST

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the pricing of its upsized underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $35.00 per share. In addition, Arcutis has granted the... More

Arcutis Biotherapeutics Inc. (ARQT) Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream in Plaque Psoriasis

February 1, 2021 7:31 AM EST

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with... More